Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Accumulated Depreciation of $9.1 million for Q1 2026, up 39.36% year-over-year from $6.5 million in Q1 2025, and up 7.67% quarter-over-quarter from $8.5 million in Q4 2025.
Artiva Biotherapeutics (ARTV) Accumulated Depreciation (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Accumulated Depreciation for 4 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Depreciation rose 39.36% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (up 39.36% YoY), while the FY2025 annual figure was $8.5 million, up 42.78% from the prior year.
- Accumulated Depreciation improved to $9.1 million in Q1 2026 per ARTV's latest filing, from $8.5 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $9.1 million in Q1 2026 and bottomed at $3.5 million in Q4 2023.
- Historically, Accumulated Depreciation has averaged $6.7 million across 4 years, with a median of $6.8 million in 2025.
- Annual changes were most pronounced in 2024 — Accumulated Depreciation soared 67.7% — and 2026, when it jumped 39.36%.
- Artiva Biotherapeutics' Accumulated Depreciation stood at $3.5 million in 2023, then jumped by 67.7% to $5.9 million in 2024, then soared by 42.78% to $8.5 million in 2025, then advanced by 7.67% to $9.1 million in 2026.
- Business Quant data shows ARTV's Accumulated Depreciation at $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $7.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.78 Mn |
| Mar 31, 2026 | 9.11 Mn |
| Dec 31, 2025 | 8.46 Mn |
| Sep 30, 2025 | 7.81 Mn |
| Jun 30, 2025 | 7.16 Mn |
| Mar 31, 2025 | 6.53 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | 5.33 Mn |
| Dec 31, 2023 | 3.53 Mn |